Rachel Cafferty
Concepts (91)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Service, Hospital | 11 | 2026 | 2363 | 3.100 |
Why?
| | Suicide | 6 | 2026 | 647 | 2.440 |
Why?
| | Mass Screening | 5 | 2026 | 1307 | 2.050 |
Why?
| | Suicidal Ideation | 4 | 2025 | 543 | 1.310 |
Why?
| | Suicide, Attempted | 2 | 2025 | 391 | 1.300 |
Why?
| | Caregivers | 3 | 2026 | 1080 | 1.050 |
Why?
| | Ambulatory Care | 1 | 2026 | 628 | 0.670 |
Why?
| | Mental Health Services | 1 | 2025 | 450 | 0.620 |
Why?
| | Neurocysticercosis | 1 | 2019 | 8 | 0.580 |
Why?
| | Adolescent | 14 | 2026 | 22557 | 0.560 |
Why?
| | Sexually Transmitted Diseases | 1 | 2020 | 163 | 0.520 |
Why?
| | Physicians, Primary Care | 1 | 2020 | 210 | 0.510 |
Why?
| | Child | 14 | 2026 | 22693 | 0.460 |
Why?
| | Sexual and Gender Minorities | 1 | 2020 | 269 | 0.440 |
Why?
| | Seizures | 1 | 2019 | 489 | 0.420 |
Why?
| | Interviews as Topic | 2 | 2025 | 930 | 0.330 |
Why?
| | Risk Factors | 4 | 2026 | 10921 | 0.310 |
Why?
| | Firearms | 2 | 2026 | 444 | 0.270 |
Why?
| | Female | 13 | 2026 | 79499 | 0.260 |
Why?
| | Male | 12 | 2026 | 73396 | 0.250 |
Why?
| | Qualitative Research | 2 | 2025 | 1734 | 0.250 |
Why?
| | Mental Disorders | 2 | 2026 | 1148 | 0.240 |
Why?
| | Humans | 18 | 2026 | 146342 | 0.240 |
Why?
| | Brain | 1 | 2019 | 2991 | 0.240 |
Why?
| | Guanidinoacetate N-Methyltransferase | 1 | 2025 | 4 | 0.230 |
Why?
| | Brain Diseases, Metabolic, Inborn | 1 | 2025 | 6 | 0.230 |
Why?
| | Plasma Membrane Neurotransmitter Transport Proteins | 1 | 2025 | 6 | 0.230 |
Why?
| | Wounds, Gunshot | 2 | 2026 | 262 | 0.220 |
Why?
| | Privacy | 1 | 2025 | 41 | 0.220 |
Why?
| | Movement Disorders | 1 | 2025 | 68 | 0.210 |
Why?
| | Retrospective Studies | 6 | 2025 | 17438 | 0.210 |
Why?
| | Risk Assessment | 2 | 2026 | 3712 | 0.210 |
Why?
| | Interrupted Time Series Analysis | 1 | 2024 | 73 | 0.210 |
Why?
| | Membrane Transport Proteins | 1 | 2025 | 154 | 0.200 |
Why?
| | Neuroimaging | 1 | 2025 | 307 | 0.190 |
Why?
| | Psychotic Disorders | 1 | 2025 | 188 | 0.190 |
Why?
| | Health Education | 1 | 2026 | 346 | 0.180 |
Why?
| | Holidays | 1 | 2020 | 9 | 0.150 |
Why?
| | Documentation | 1 | 2022 | 202 | 0.150 |
Why?
| | Minnesota | 1 | 2020 | 167 | 0.150 |
Why?
| | Taenia solium | 1 | 2019 | 5 | 0.150 |
Why?
| | Neglected Diseases | 1 | 2019 | 5 | 0.140 |
Why?
| | Public Health | 1 | 2024 | 574 | 0.140 |
Why?
| | Anthelmintics | 1 | 2019 | 13 | 0.140 |
Why?
| | Emergency Medical Services | 1 | 2026 | 680 | 0.140 |
Why?
| | Gender Identity | 1 | 2020 | 132 | 0.140 |
Why?
| | Africa | 1 | 2019 | 119 | 0.140 |
Why?
| | Adalimumab | 1 | 2017 | 53 | 0.130 |
Why?
| | Cross-Sectional Studies | 2 | 2026 | 5899 | 0.130 |
Why?
| | Arthritis, Juvenile | 1 | 2017 | 64 | 0.120 |
Why?
| | Sarcoma, Myeloid | 1 | 2016 | 6 | 0.120 |
Why?
| | Anticonvulsants | 1 | 2019 | 253 | 0.120 |
Why?
| | Orbital Neoplasms | 1 | 2016 | 28 | 0.120 |
Why?
| | Uveitis | 1 | 2017 | 152 | 0.120 |
Why?
| | Mental Health | 1 | 2023 | 779 | 0.120 |
Why?
| | Emigrants and Immigrants | 1 | 2019 | 160 | 0.120 |
Why?
| | Pandemics | 1 | 2024 | 1707 | 0.110 |
Why?
| | Sexual Behavior | 1 | 2020 | 490 | 0.110 |
Why?
| | Antirheumatic Agents | 1 | 2017 | 309 | 0.110 |
Why?
| | Glucocorticoids | 1 | 2019 | 536 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1503 | 0.110 |
Why?
| | Surveys and Questionnaires | 1 | 2025 | 6073 | 0.090 |
Why?
| | Hospitalization | 1 | 2023 | 2475 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 2 | 2025 | 3926 | 0.080 |
Why?
| | Adult | 3 | 2026 | 41087 | 0.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1998 | 0.060 |
Why?
| | Language Development Disorders | 1 | 2025 | 40 | 0.060 |
Why?
| | Creatine | 1 | 2025 | 63 | 0.050 |
Why?
| | Video Recording | 1 | 2026 | 219 | 0.050 |
Why?
| | Delphi Technique | 1 | 2026 | 350 | 0.050 |
Why?
| | Safety | 1 | 2024 | 347 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2026 | 1135 | 0.040 |
Why?
| | Pediatrics | 1 | 2026 | 1124 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2026 | 1408 | 0.030 |
Why?
| | Child, Preschool | 2 | 2025 | 11913 | 0.030 |
Why?
| | Retreatment | 1 | 2016 | 79 | 0.030 |
Why?
| | Animals | 1 | 2019 | 38107 | 0.030 |
Why?
| | Patient Discharge | 1 | 2023 | 997 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 790 | 0.030 |
Why?
| | Colorado | 1 | 2026 | 4595 | 0.030 |
Why?
| | Treatment Failure | 1 | 2016 | 361 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2025 | 2786 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2023 | 5439 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1271 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 447 | 0.020 |
Why?
| | Neoadjuvant Therapy | 1 | 2016 | 475 | 0.020 |
Why?
| | Recurrence | 1 | 2016 | 1133 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2017 | 11821 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2016 | 893 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2016 | 1339 | 0.020 |
Why?
| | Young Adult | 1 | 2024 | 14330 | 0.020 |
Why?
|
|
Cafferty's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|